SCHEMBL2301431

SCHEMBL2301431

C=Cc1cccc(NC(=O)c2ccccc2C(=O)c2ccc3nc(NC(=O)O)[nH]c3c2)c1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.54
▸ BRAF P15056 5/20 0.54
▸ ALDH1A1 P00352 4/20 0.46
▸ ABL1 P00519 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ CYP2C9 P11712 3/20 0.46
▸ KDR P35968 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ ABCC4 O15439 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ XIAP P98170 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299028 0.88 RAF1 (0.57) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL2296483 0.87 RAF1 (0.56) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL2357595 0.87 RAF1 (0.56) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL2299782 0.85 RAF1 (0.54) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL1469056 0.84 RAF1 (0.45) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL2297139 0.82 RAF1 (0.57) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL5038620 0.81 POLB (0.51) ALDH1A1HTTMAPTKMT2ANPC1
SCHEMBL3857514 0.81 RAF1 (0.38) RAF1BRAFALDH1A1LMNACYP2C9
SCHEMBL2299292 0.81 RAF1 (0.55) RAF1BRAFALDH1A1ABL1LMNA
SCHEMBL2300130 0.81 RAF1 (0.57) RAF1BRAFALDH1A1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
WO-2009017838-A2 COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS EXELIXIS, INC. (US) 2009-02-05 — — WO claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback